FDA Approves New Label for ADHD Drug FOCALIN XR(TM): Starts Working Fast and Lasts Up to and Including 12 Hours
Posted on: Wednesday, 24 May 2006, 12:00 CDT
NEW YORK, May 23 /PRNewswire/ -- THIS IS A MULTIVU SPECIAL REPORT.
THERE'S NEW INFORMATION FOR PEOPLE WITH A-D-H-D. TWO STUDIES IN PEDIATRIC PATIENTS SHOWED THAT FOCALIN XR WORKS FAST AND LASTS UP TO 12 HOURS. THE FDA JUST APPROVED THE ADDITION OF THIS INFORMATION TO THE FOCALIN XR LABEL.
DOCTOR LENARD ADLER, NYU SCHOOL OF MEDICINE:
"Ideally when we're looking for effects of ADHD medication, we're looking for a medicine that will start quickly, have effects throughout the day and this is what Focalin XR has been shown to do."
FOR ERIN HUNTER, A COLLEGE STUDENT, THIS IS VERY IMPORTANT:
"Being a college student, going from school to work, I am able to stay focused, and I think that the extended release Focalin XR helps me with that."
FOCALIN XR IS INDICATED FOR THE TREATMENT OF ADHD IN PATIENTS AGED SIX YEARS AND OLDER. FOCALIN XR IS INDICATED AS AN INTEGRAL PART OF A TOTAL TREATMENT PROGRAM FOR PEOPLE WITH ADHD THAT MAY INCLUDE PSYCHOLOGICAL, EDUCATIONAL OR SOCIAL MEASURES.
FOR MORE INFORMATION ABOUT A-D-H-D TREATMENT WITH FOCALIN X-R, VISIT FocalinXR.COM. I'M CHRISTIANE ARBESU.
READ FAIR BALANCE: As with all medications, individual treatment results may vary.
Like most drugs approved for the treatment of ADHD, Focalin XR is contraindicated in patients known to be hypersensitive to the drug or to methylphenidate, in patients with glaucoma, and in patients with motor tics or with a family history or diagnosis of Tourette's syndrome. It is also contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result). In addition, like most drugs approved for the treatment of ADHD, Focalin XR is a schedule II drug and should be given cautiously to patients with a history of drug dependence or alcoholism. Focalin XR should generally not be used in those who have structural cardiac abnormalities.
AUDIO PROVIDED BY: Novartis Pharmaceuticals Corporation
Audio: http://www.prnewswire.com/broadcast/23285/consumer.html
Novartis Pharmaceuticals Corporation
CONTACT: FOR STORY INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313, EXT. 3 OR EMAIL RADIO@MULTIVU.COM
Web site: http://focalinxr.com/
Source: PRNewswire
Related Articles
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- FDA Approves J&J's Concerta for Treatment of ADHD in Adults
- FDA Approves CONCERTA(R) (Methylphenidate HCI) Extended-Release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
- Shire Files Vyvanse Drug for the Treatment of ADHD in Adults
- Health Boards Told to Use Sight-Sav Ing Treatment Ministers Say Drug Was Approved in July
- Shire Seeks Approval for New ADHD Drug
- Shire Seeks Approval for Long-Acting ADHD Drug
- FDA Sets Date for Decision on Shire ADHD Drug
- Psychiatric Side Effects of ADHD Drugs Probed
- FDA Probing ADHD Drugs for Side Effects
User Comments (0)
RSS Feeds